Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Genitourinary 2Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Kidney Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 65Nivolumab 57Magnetic Resonance Spectroscopy 53enzalutamide 39Abiraterone Acetate 37Radiosurgery 36Gemcitabine 35Specimen Handling 32Radiotherapy 32Ipilimumab 32Androgen Antagonists 32Prednisone 31apalutamide 28Cisplatin 28Docetaxel 27Leuprolide 26atezolizumab 25Carboplatin 25durvalumab 23cabozantinib 22darolutamide 20acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 19olaparib 18Goserelin 17Radiation 16Gonadotropin-Releasing Hormone 16Biopsy 16gallium 68 PSMA-11 15Pluvicto 15avelumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × guadecitabine × Genitourinary × Clear all
NCT03308396 2022-02-17

Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

Big Ten Cancer Research Consortium

Phase 1/2 Active not recruiting
57 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03179943 2021-11-04

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Fox Chase Cancer Center

Phase 2 Active not recruiting
21 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡